Abraham Weizman

40.4k total citations · 1 hit paper
981 papers, 28.4k citations indexed

About

Abraham Weizman is a scholar working on Psychiatry and Mental health, Clinical Psychology and Molecular Biology. According to data from OpenAlex, Abraham Weizman has authored 981 papers receiving a total of 28.4k indexed citations (citations by other indexed papers that have themselves been cited), including 423 papers in Psychiatry and Mental health, 253 papers in Clinical Psychology and 145 papers in Molecular Biology. Recurrent topics in Abraham Weizman's work include Schizophrenia research and treatment (187 papers), Bipolar Disorder and Treatment (139 papers) and Tryptophan and brain disorders (107 papers). Abraham Weizman is often cited by papers focused on Schizophrenia research and treatment (187 papers), Bipolar Disorder and Treatment (139 papers) and Tryptophan and brain disorders (107 papers). Abraham Weizman collaborates with scholars based in Israel, United States and United Kingdom. Abraham Weizman's co-authors include Moshe Gavish, Rachel Maayan, Michael Poyurovsky, Irit Gil‐Ad, Moria Golan, Dov Aizenberg, Haggai Hermesh, Roberto Mester, Moshe Rehavi and Amos Frisch and has published in prestigious journals such as The Lancet, Nature Communications and Neuron.

In The Last Decade

Abraham Weizman

964 papers receiving 27.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function

2006 1.1k citations Abraham Weizman, Moshe Gavish et al. profile →

Peers

Countries citing papers authored by Abraham Weizman

Since Specialization

Citations

This map shows the geographic impact of Abraham Weizman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham Weizman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham Weizman more than expected).

Fields of papers citing papers by Abraham Weizman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham Weizman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham Weizman. The network helps show where Abraham Weizman may publish in the future.

Co-authorship network of co-authors of Abraham Weizman

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham Weizman. A scholar is included among the top collaborators of Abraham Weizman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham Weizman. Abraham Weizman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atovaquone-proguanil and reduced digestive cancer risk: a Toxoplasma gondii connection 2025 ·Gut Microbes ·Ariel Israel, Sarah Israel, Abraham Weizman, Shai Ashkenazi, Shlomo Vinker, Eli Magen, Eugene Merzon	1
2	Increased Prevalence of Attention Deficit Hyperactivity Disorder in Individuals with Selective Immunoglobulin A Deficiency: A Nationwide Case–Control Study 2024 ·Journal of Clinical Medicine ·Eugene Merzon, (unknown), Shai Ashkenazi, Eli Magen, Iris Manor, Abraham Weizman, Ilan Green, Avivit Golan‐Cohen, (unknown), Shlomo Vinker, Ariel Israel	0
3	Gestational hemodilution as a putative risk factor for postpartum depression: A large-scale nationwide longitudinal cohort study 2023 ·Journal of Affective Disorders ·Eldar Hochman, Becca Feldman, Abraham Weizman, Amir Krivoy, Shay Gur, Eran Barzilay, (unknown), (unknown), Gabriella Lawrence	0
4	Differences in Telomere Length between Adolescent Females with Anorexia Nervosa Restricting Type and Anorexia Nervosa Binge-Purge Type 2023 ·Nutrients ·Orit Uziel, (unknown), Einat Beery, Yael Doreen Lewis, Ron Loewenthal, (unknown), (unknown), Abraham Weizman, Dan J. Stein	2
5	The Association between Glucose 6-Phosphate Dehydrogenase Deficiency and Attention Deficit/Hyperactivity Disorder 2023 ·Nutrients ·Eugene Merzon, Eli Magen, Shai Ashkenazi, Abraham Weizman, Iris Manor, (unknown), Ilan Green, Avivit Golan‐Cohen, Shlomo Vinker, Stephen V. Faraone, Ariel Israel	1
6	The Effect of Dehydroepiandrosterone Administration during Rehabilitation on White Matter Integrity Among Individuals With Polysubstance Use Disorder 2023 ·Journal of Addiction Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Rachel Maayan, Paola Rosca, Abraham Weizman, (unknown), Gal Yadid, Roee Admon	1
7	Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression 2021 ·Brain Behavior & Immunity - Health ·(unknown), (unknown), (unknown), (unknown), Ilan Green, Avivit Golan‐Cohen, Shlomo Vinker, Iris Manor, Abraham Weizman, Eli Magen	15
8	Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy 2021 ·Journal of Psychiatric Research ·(unknown), Libi Hertzberg, Guy Shapira, Aviv Segev, Israel Krieger, Uri Nitzan, Yuval Bloch, Nir Pillar, (unknown), Abraham Weizman, David Gurwitz, Noam Shomron	12
9	The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson’s Disease 2021 ·Biology ·(unknown), Nunzio Denora, Valentino Laquintana, (unknown), Abraham Weizman, Moshe Gavish	3
10	The association of non-suicidal self-injurious and suicidal behaviors with religiosity in hospitalized Jewish adolescents 2020 ·Clinical Child Psychology and Psychiatry ·(unknown), (unknown), (unknown), (unknown), (unknown), Amir Krivoy, (unknown), Yoav Kohn, Abraham Weizman, Gal Shoval	4
11	Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment 2017 ·Schizophrenia Research ·Amir Krivoy, Eldar Hochman, Kyra-Verena Sendt, (unknown), (unknown), (unknown), Abraham Weizman, Michal Taler	26
12	Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects 2014 ·Journal of Psychiatric Research ·Miri Carmel, Omer Zarchi, Elena Michaelovsky, Amos Frisch, Miriam Patya, Tamar Green, Doron Gothelf, Abraham Weizman	24
13	The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial 2012 ·Journal of Neural Transmission ·Tamar Green, (unknown), Amos Frisch, Omer Zarchi, Abraham Weizman, Doron Gothelf	10
14	Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive Behavior 2011 ·Clinical Neuropharmacology ·Pavel Golubchik, Jonathan Sever, Abraham Weizman	40
15	Prevalence of Dementia in an Elderly illiterate Native Mexican Population of Indigenous Origin 2011 ·Journal of Public Health and Epidemiology ·Rafael Stryjer, Baruch Spivak, Roni Shiloh, (unknown), Abraham Weizman, (unknown), Martin Rabey	2
16	Stroop performance in major depression: Selective attention impairment or psychomotor slowness? 2009 ·Journal of Affective Disorders ·Semion Kertzman, Ilya Reznik, Tzipi Hornik‐Lurie, Abraham Weizman, Moshe Kotler, Daniela Amital	46
17	Obsessive-compulsive disorder and comorbidity 2006 ·Nova Science Publishers eBooks ·Ruth Gross‐Isseroff, Abraham Weizman	8
18	[Pharmacotherapy in schizophrenia--comparison of second generation antipsychotic agents]. 2005 ·PubMed ·Yuval Melamed, Boris Finkel, Yoram Barak, (unknown), (unknown), Abraham Weizman, Avi Bleich	2
19	Myotoxicity and Neurotoxicity during Clozapine Treatment 2000 ·Clinical Neuropharmacology ·Ilya Reznik, (unknown), Roberto Mester, Moshe Kotler, I Sarova-Pinhàs, Baruch Spivak, Abraham Weizman	27
20	Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients 2000 ·Biological Psychiatry ·Rachel Maayan, (unknown), Daniel Grupper, Mordechai Weiss, Biana Shtaif, (unknown), Abraham Weizman	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact